- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- February 2021
- 360 Pages
United States
From €2320EUR$2,400USD£1,994GBP
- Report
- February 2019
- 105 Pages
Global
From €1247EUR$1,290USD£1,072GBP
- Report
- January 2022
- 110 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Drug Pipelines
- June 2019
- 579 Pages
Global
€21268EUR$22,000USD£18,280GBP
- Report
- June 2019
- 15 Pages
Global
€9667EUR$10,000USD£8,309GBP
- Report
- July 2019
- 16 Pages
Global
€9667EUR$10,000USD£8,309GBP
- Report
- June 2019
- 16 Pages
Global
€9667EUR$10,000USD£8,309GBP
Delstrigo is a combination antiretroviral drug used to treat HIV/AIDS. It is a fixed-dose combination of three drugs: doravirine, lamivudine, and tenofovir disoproxil fumarate. Delstrigo is used to treat HIV-1 infection in adults and adolescents aged 12 years and older. It is not recommended for use in children under 12 years of age. Delstrigo works by blocking the action of HIV-1 reverse transcriptase, an enzyme that is essential for the virus to replicate. This helps to reduce the amount of HIV-1 in the body and prevent further damage to the immune system.
Delstrigo is available in the market as a tablet and is taken once daily with food. It is important to take Delstrigo exactly as prescribed by the doctor. Delstrigo should not be used in combination with other antiretroviral drugs.
Companies in the Delstrigo market include Merck & Co., Inc., Gilead Sciences, Inc., Bristol-Myers Squibb Company, and ViiV Healthcare. Show Less Read more
